Bullish
Parabilis Medicines successfully raised $670 million in an above-range initial public offering, selling 33.5 million shares at $20 each. The company a...
Neutral
Regeneron Pharmaceuticals (REGN) has received support from the World Health Organization (WHO) for its antibody therapy, maftivimab, to be evaluated i...
Bullish
Parabilis Medicines, a Cambridge-based cancer-focused biotech company, is planning a $450 million IPO with backing from Regeneron. The company has alr...
Neutral
Parabilis Medicines (PBLS), a cancer drug developer with a research collaboration with Regeneron (REGN), is aiming to raise up to $476 million in its ...
Bullish
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is set to present clinical data at the American Diabetes Association 86th Scientific Sessions and the En...
Bullish
Regeneron has expanded its collaboration with CytomX Therapeutics, increasing potential payments by up to $2 billion and adding eight more targets for...
Bullish
Regeneron (NASDAQ: REGN) is set to present new clinical and preclinical data at the ADA (June 5-8) and ENDO (June 13-16) 2026 conferences. Key present...
Neutral
Bank of New York Mellon Corp boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 13.8% during the 4th qua...
Bullish
CytomX Therapeutics (CTMX) announced an expanded collaboration with Regeneron Pharmaceuticals, potentially worth up to $4 billion, to develop bispecif...
Bullish
CytomX Therapeutics shares rose over 4% in premarket trading after announcing an expanded collaboration with Regeneron Pharmaceuticals, resulting in a...
CytomX has expanded its collaboration with Regeneron Pharmaceuticals to develop conditionally activated bispecific cancer therapies, combining CytomX'...
Neutral
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This i...
Neutral
Commonwealth of Pennsylvania Public School Empls Retrmt SYS decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Re...
Neutral
Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Medicines Agency (EMA) has accepted for accelerated review its Marketing Authorizat...
Neutral
National Pension Service has increased its stake in Regeneron Pharmaceuticals, Inc. by 29.8% during the fourth quarter, purchasing an additional 82,85...
Bullish
Fideuram Asset Management Ireland dac has invested $10.12 million in Regeneron Pharmaceuticals, Inc., acquiring 13,111 shares in the fourth quarter. T...
Bearish
Pomerantz LLP is investigating potential securities fraud claims against Regeneron Pharmaceuticals, Inc. following a significant drop in its stock pri...
Bearish
Grabar Law Office is investigating claims on behalf of long-term shareholders of Commvault Systems, Inc. (CVLT), MongoDB, Inc. (MDB), New Era Energy &...
Bearish
Canaccord and Wolfe Research have both cut their price targets for Regeneron Pharmaceuticals (REGN) after its Phase 3 study of fianlimab+cemiplimab fa...
Bullish
Regeneron Pharmaceuticals, Inc. has announced plans to establish a Global Capability Centre (GCC) in Hyderabad, India, with operations expected to com...